The Next Frontier of Cellular Therapy in Oncology
ONCOLOGY · 2026-10-28 · 40 (7)
DOI: 10.46883/2026.25921245 ↗Abstract
The National Immune Cell Effector Therapy (ICE-T) Symposium convened on September 27, 2025, in Kansas City, Kansas, bringing together hematologists, oncologists, nurses, and researchers to address the rapidly evolving landscape of immune effector therapies. Sessions spanned chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, with emphasis on their expanding role in multiple myeloma, lymphomas, and, increasingly, autoimmune diseases such as systemic lupus erythematosus. Presenters explored both the clinical promise and the practical challenges of these therapies across a wide range of settings. Collectively, the meeting underscored a shift toward making cellular therapy safer, more scalable, and more equitably accessible.
EUVIMED